Corcept Therapeutics CORT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$31.76M-231% | $24.29M+23.5% | $19.67M-44.0% | $35.15M+71.1% | $20.55M-33.2% | ||
| $598K+107% | $289K0.0% | $289K+165% | $109K-76.4% | $462K+64.4% | ||
| $23.04M+11.0% | $20.77M-9.2% | $22.88M+20.3% | $19.02M-12.9% | $21.83M+30.0% | ||
| -$13.11M+13.6% | -$15.18M— | —— | -$17.76M-29.6% | -$13.71M-255% | ||
| -$20.71M— | —— | $5.06M+84.2% | $2.75M-65.0% | $7.84M— | ||
| $3.27M— | $0-100% | $3.94M-14.8% | $4.63M+865% | -$605K— | ||
| -$7.64M-227% | $6M-45.1% | $10.92M— | —— | $12.57M+505% | ||
| -$9.38M— | —— | $17.16M+192% | $5.88M+200% | -$5.87M-155% | ||
| -$4.74M-247% | $3.22M-76.0% | $13.46M— | —— | $13.53M— | ||
| -$16.77M-144% | $38.45M-29.4% | $54.48M+23.0% | $44.3M+829% | $4.77M-92.1% | ||
| $201K+302% | $50K— | $0-100% | $57K-45.2% | $104K-14.0% | ||
| $4.54M— | —— | $14.65M-79.1% | $70.13M+2,312% | -$3.17M+95.1% | ||
| $0— | $0-100% | $42.46M-58.8% | $103.02M+276% | $27.43M— | ||
| $5.76M-84.2% | $36.54M+348% | $8.15M-34.4% | $12.43M-21.5% | $15.83M+127% | ||
| $760K+102% | -$31.22M+32.7% | -$46.41M+54.9% | -$102.93M-159% | -$39.8M-772% | ||
| -$287K— | —— | —— | $1.44M+301% | $358K+147% | ||
| -$11.76M-153% | -$4.64M— | —— | —— | -$37.85M-293% | ||
| —— | $3.24M0.0% | $3.24M0.0% | $3.24M0.0% | $3.24M-78.5% | ||
| —— | $1.28M0.0% | $1.28M0.0% | $1.28M0.0% | $1.28M-53.3% | ||
| -$836K— | —— | -$1.01M+23.4% | -$1.31M+22.5% | -$1.69M— | ||
| $137K— | —— | —— | —— | -$8.61M— | ||
| -$9.38M— | —— | $17.16M+192% | $5.88M+200% | -$5.87M-155% | ||
| -$4.74M-247% | $3.22M-76.0% | $13.46M— | —— | $13.53M— | ||
| $2.54M+3.1% | $2.46M+13.4% | $2.17M-33.7% | $3.28M+91.0% | $1.72M+11.9% | ||
| —— | $3.24M0.0% | $3.24M0.0% | $3.24M0.0% | $3.24M-78.5% | ||
| $4.34M-35.8% | $6.76M+17.7% | $5.74M-15.5% | $6.8M+29.2% | $5.26M-25.0% | ||
| -$16.97M-144% | $38.4M-29.5% | $54.48M+23.1% | $44.24M+848% | $4.67M-92.2% | ||
| -$16.97M-144% | $38.4M-29.5% | $54.48M+23.1% | $44.24M+848% | $4.67M-92.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Corcept Therapeutics generate?
- Corcept Therapeutics (CORT) generated $120.5M in operating cash flow over the trailing twelve months.
- What is Corcept Therapeutics's free cash flow?
- After $308.0K of capital expenditures, Corcept Therapeutics's free cash flow was $120.1M over the trailing twelve months, down 32.1% year over year.
- Where does Corcept Therapeutics's cash flow data come from?
- Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
